J&J's Doxil fixes put Sun Pharma's supply deal in jeopardy

Sun Pharmaceutical Industries shares fell on worries that the Indian drugmaker will lose a contract to sell its version of the cancer drug Doxil in the U.S., after Johnson & Johnson ($JNJ) said it would resume supplying the scarce drug. Report